marijuana stocks

Cannabis Sativa, Inc. Announces Signing of Business Consulting Agreement


Cannabis Sativa, Inc. (OTCQB:CBDS) (referred to collectively with its subsidiaries as “CBDS”) today announced that it has signed a consulting agreement with consultants Jeff W. Holmes, Greg W. Holmes and Kevin J. Asher. Under the terms of the agreement the consultants will assist Cannabis Sativa, Inc. to build a comprehensive financial business model, develop and structure financial instruments to assist the company in capital raises and help prepare Cannabis Sativa, Inc. for the filing and application process for the NASDAQ markets, among other services.

“We are excited to work with Cannabis Sativa, Inc. which has an exemplary management team and board of directors,” said Jeff W. Holmes. “We believe in the legitimacy and market growth potential of the marijuana industry and we have identified Cannabis Sativa, Inc. as a company we believe to be well positioned in the cannabis market.”

“With the signing of the consulting agreement we are committed to move the company to the next level and execute on our business plan,” said former New Mexico governor Gary Johnson, CEO of Cannabis Sativa, Inc. “Further Jeff Holmes, Greg Holmes and Kevin Asher have extensive experience working with public companies and they can assist us with our strategic planning, development and guidance that we need as a public company.”

About CBDS

Cannabis Sativa, Inc. is engaged through its recently acquired subsidiary, Kush, in the research, development and licensing of specialized natural cannabis products, including cannabis formulas, edibles, topicals, strains, recipes and delivery systems. CBDS also offers the Skin Garden line of cosmetic products through its subsidiary, Wild Earth Naturals, which are designed to use organic and natural ingredients, including hemp seed oil, to benefit inner wellbeing as well as outward appearance.

Forward-Looking Statements

This press release contains “forward-looking statements.” Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Cannabis Sativa, Inc.
Media Contact:
Michael Pickens, 209-402-7440
Investor Information:

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 |
1 comment
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

 Neptune Wellness Solutions Inc. (NEPT) Wellness Chief Executive Officer Michael Cammarata on Successful U.S. House of Representatives Vote to Decriminalize Marijuana

Statement from Neptune Wellness Chief Executive Officer Michael Cammarata on Successful U.S.…

$IIVXX Premium Quality Cannabis Extracts Now Available

IVXX Premium Quality Cannabis Extracts are Now Available to Qualified California Medical…

Lexaria Bioscience Corp. (LXRP) Renews Contracts with Senior Management and Cancels Options

Lexaria Bioscience Renews Contracts with Senior Management and Cancels Options Lexaria Bioscience…

Tetra Bio-Pharma Inc. (TBPMF) Provides Update on Market Potential of ARDS-003

Tetra Bio-Pharma Provides Update on Market Potential of ARDS-003 Tetra Bio-Pharma Inc.…